Hold Rating on Atea Pharmaceuticals: Analysis of Clinical Programs, Financial Health and Future Prospects
TipRanksNov 10, 2023 19:32
Atea Pharmaceuticals Analyst Ratings
BenzingaAug 10, 2023 17:28
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
TipRanksMay 23, 2023 23:45
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
TipRanksMay 12, 2023 00:47
Atea Pharmaceuticals (AVIR) Gets a Hold From J.P. Morgan
TipRanksMar 17, 2023 00:31
JPMorgan Adjusts Atea Pharmaceuticals Price Target to $8 From $12, Maintains Neutral Rating
MT NewswiresMar 16, 2023 21:29
JP Morgan Maintains Neutral on Atea Pharmaceuticals, Lowers Price Target to $8
BenzingaMar 16, 2023 20:51
SVB Securities Reaffirms Their Hold Rating on Atea Pharmaceuticals (AVIR)
TipRanksMar 3, 2023 14:21
SVB Securities Adjusts Atea Pharmaceuticals' Price Target to $6 From $8, Keeps Market Perform Rating
MT NewswiresJan 27, 2023 23:47
Atea Pharmaceuticals (AVIR) Receives a Hold From SVB Securities
TipRanksJan 27, 2023 20:27
Atea Pharmaceuticals Analyst Ratings
Benzinga Analyst RatingsJan 27, 2023 19:51
Morgan Stanley Sticks to Its Sell Rating for Atea Pharmaceuticals (AVIR)
TipRanksJan 25, 2023 00:30
Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $4 From $7, Maintains Underweight Rating
MT NewswiresJan 24, 2023 22:50
Atea Pharmaceuticals Analyst Ratings
Benzinga Analyst RatingsJan 24, 2023 21:16
Morgan Stanley Maintains Underweight on Atea Pharmaceuticals, Lowers Price Target to $4
Benzinga Real-time NewsJan 24, 2023 21:16
Atea Pharmaceuticals (AVIR) Gets a Hold From SVB Securities
TipRanksNov 10, 2022 12:40
No Data
No Data